impact factor
logo
 

Full Papers

 

HLA-B*27 is significantly enriched in Nordic patients with psoriatic arthritis mutilans


1, 2, 3, 4, 5, 6, 7, 8

 

  1. Dermatology Division, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. pernilla.nikamo@ki.se
  2. Centre for Rheumatology Research, Landspitali University Hospital and Faculty of Medicine, The University of Iceland, Reykjavik, Iceland.
  3. Helsinki Medical Imaging Center, Helsinki University Central Hospital, Helsinki, Finland.
  4. Department of Rheumatology, Odense University Hospital, Odense, Denmark.
  5. Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
  6. Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden.
  7. Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  8. Dermatology Division, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

CER13473
Full Papers

purchase article

PMID: 32896263 [PubMed]

Received: 20/04/2020
Accepted : 15/06/2020
In Press: 04/09/2020

Abstract

OBJECTIVES:
The genetic contribution to psoriatic disease is substantial with a dominating influence of the HLA region. The profile of HLA class I genotypes likely contributes to shaping clinical phenotypes. Herein we aimed to explore such genotypes in cohorts of closely characterised subsets of psoriatic disease with special focus on psoriatic arthritis mutilans (PAM), a severe and rare form of psoriatic arthritis (PsA).
METHODS:
Cohorts of patients with the diagnosis of psoriasis vulgaris with or without arthritis (n=1217), psoriasis without arthritis (n=534), psoriatic arthritis without mutilating disease (n=337) and psoriatic arthritis mutilans (n=63) were collected and genotyped for HLA class I and II genes, with standardised methodologies. Cases were compared with a healthy control population (n=2468). Case-only and case-control association tests were performed to address the hypothesis of genetic contribution to clinical phenotypes.
RESULTS:
The presence of HLA-B*27 was strikingly increased in PAM (45%) compared with PsA without mutilating disease (13%) and with healthy controls (13%). However, within the PAM population, HLA-B*27 did not correlate with clinical markers such as number of mutilating joints, radiographic scoring, disease duration and age of disease onset.
CONCLUSIONS:
HLA-B*27 emerges as an important genotype marker for PAM.

Rheumatology Article